Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service—Utilising cerebrospinal fluid biomarkers and appropriate use criteria

OBJECTIVES: Aducanumab is a monoclonal antibody which has recently been licenced for use by the food and drug administration for treatment of patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia. Appropriate use criteria (AUC) for Aducanumab in clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Togher, Zara, Dolphin, Helena, Russell, Caoimh, Ryan, Marie, Kennelly, Séan P., O'Dowd, Séan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542503/
https://www.ncbi.nlm.nih.gov/pubmed/35861223
http://dx.doi.org/10.1002/gps.5789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542503/
https://www.ncbi.nlm.nih.gov/pubmed/35861223
http://dx.doi.org/10.1002/gps.5789

Ejemplares similares